Navigation Links
Rigel Announces Presentations at Two Investor Conferences
Date:10/28/2009

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, executive vice president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows:

    Oppenheimer 20th Annual Healthcare Conference
    Waldorf Astoria, New York City, NY
    November 3, 2:10 p.m. EST
    Speaker: Raul R. Rodriguez

    Credit Suisse 18th Annual Healthcare Conference
    Arizona Biltmore Hotel, Phoenix, AZ
    November 11, 2:00 p.m. MST
    Speaker: James M. Gower

Both presentations will be webcast. To access the live webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

    Contact: Raul R. Rodriguez
    Phone: 650-624-1302
    Email: invrel@rigel.com

    Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
    Phone: 650.430.3777
    Email: susan@alchemyemail.com

SOURCE Rigel Pharmaceuticals, Inc.


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
2. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
3. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
4. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
5. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
6. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
7. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
8. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
9. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
10. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
11. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jan. 17, 2017 Paragon Bioservices received a ... development services for a variety of National ... medical product development activities. The IDIQ mechanism will ... for task order awards up to $159 million. ... manufacturing and process development of biopharmaceuticals, is one ...
(Date:1/17/2017)... , Jan. 17, 2017  Pennsylvania Secretary ... announced applications for medical marijuana growers/processors and dispensaries ... Marijuana Program website . Permit applications will be ... "This is an important step forward ... desperately need it," Secretary Murphy said. "We,ve developed ...
(Date:1/17/2017)... IRVINE, Calif. , Jan. 17, 2017  Edwards ... leader in patient-focused innovations for structural heart disease and ... for the quarter ended December 31, 2016 after the ... host a conference call at 5:00 p.m. ET that ... in the conference call, dial (877) 407-8037 or (201) ...
Breaking Medicine Technology:
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... Floundering on ... Heart Month and the perfect time for a reset. The U.S. Apple Association agrees ... to combat many of the factors that contribute to heart disease. , The U.S. ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic ... National Association of Music Merchants (NAMM) winter trade show, Booth #2876, at the ... ER•4® has long been the gold standard for high-definition, in-ear earphones. This classic ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is pleased to ... on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves more ... addition to our provider network, and the addition will benefit our members in ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... planning assistance to families and business professionals throughout central Colorado, is joining local ... families. , The Aurora Warms The Night organization is committed to breaking the ...
Breaking Medicine News(10 mins):